Zobrazení zdroje stránky Crossrosa8156

The LGBTQ+ community is considered a sexual and gender minority and is a medically underserved patient population because of healthcare disparities and specific health risks. Oncology clinical teams can provide skilled, respectful care to LGBTQ+ communities through the collection of sexual orientation and gender identity information, provision of a welcoming care environment, and appropriate use of inclusive language. Healthcare providers can play a role in prevention and detection of cancer and quality of life post-treatment through the understanding of the unique needs of the LGBTQ+ patient population as they navigate the healthcare system.<br /><br /> Symptom distress places a burden on patients and their families, but it is often not captured in nursing documentation. Using a symptom management tool, such as the Condensed Memorial Symptom Assessment Scale (CMSAS), can assist in this capture and link patients to resources.<br /><br /> The purpose of this quality improvement (QI) project was to implement the CMSAS and capture symptom burden to create a streamlined method of documentation.<br /><br /> A QI pilot was conducted on an inpatient oncology unit implementing the CMSAS. Then, surveys were provided to the patients to complete at admission and discharge. The most distressing symptoms patients reported were added into the electronic health record nursing care plan that automatically uploaded interventions based on ONS Guidelines™.<br /><br /> Patient (N = 73) symptom distress was quickly tracked, and there were no statistically significant changes in patient distress from admission to discharge, except for two symptoms.<br /><br />Patient (N = 73) symptom distress was quickly tracked, and there were no statistically significant changes in patient distress from admission to discharge, except for two symptoms.In 2004, to advance the credibility and education of the advanced practice nurse, member schools affiliated with the American Association of Colleges of Nursing (AACN) began a process to endorse a position statement on the practice doctorate in nursing. With this endorsement of advanced clinical practice nursing education at the doctoral level-an alternative to research-focused doctoral programs-the credential of doctor of nursing practice (DNP) began.Mentorship programs are an emerging strategy in the nursing profession to support and develop new staff in the field; this 12-month structured program found those in the mentoring role benefit, too. The sample included 11 oncology RNs working in the inpatient acute hospital setting, serving as mentors in the oncology nurse residency program. The results were statistically significant for compassion satisfaction, and burnout scores decreased. Qualitative analysis of the open-ended questions revealed mentors felt confident they make a difference, enhanced professional growth, and reduced burnout.Financial toxicity is well recognized as a sequela of surviving cancer. As the number of survivors is expected to increase, so are costs associated with cancer treatments. Using a nurse-pharmacist collaborative model, efforts between oncology pharmacists and nurses may inform real-world practice solutions to improve medication access. Increased medication access may reduce out-of-pocket expenses for patients with cancer.Since the inception of the COVID-19 pandemic, supply chains and hospital administrations have been trying to fulfill adequate personal protective equipment (PPE) for staff members to ensure their safety. With varying healthcare institutional policies, PPE has been deemed disposable so we do not lose its effectiveness. The Centers for Disease Control and Prevention recommends limiting the number of uses for an N95 respirator to no more than five because, at that many uses, it alters the fit for the wearer, leaving them exposed to droplets of a virus. However, when we view this single-use mentality through a sustainable and environmentally conscious lens, what impact is this having on our planet and how can we meet this new challenge.<br /><br /> Upper extremity limb precautions are recommended for patients who undergo axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB) to lower the risk of lymphedema. Limb precautions involve avoiding use of the affected arm for point-of-care testing, venipuncture, and blood pressure measurement, all of which can affect quality of life and create delays in care.<br /><br /> This review provides a summary of the evidence regarding limb precautions and evidence-based interventions to lower the risk of lymphedema after ALND or SLNB.<br /><br /> A literature search was conducted using CINAHL®; PubMed®; Education Resources Information Center; History of Science, Technology, and Medicine; Cochrane Library; and Joanna Briggs Institute databases.<br /><br /> Evidence supports exercising the affected limb, maintaining a body mass index of less than 25, and massaging to lower the risk of lymphedema. There is limited evidence for avoiding IV catheter placement and venipuncture in the affected arm following ALND and SLNB. Best practice is to assess the patient for risk factors of lymphedema before recommending selected evidence-based limb precautions.<br /><br />Evidence supports exercising the affected limb, maintaining a body mass index of less than 25, and massaging to lower the risk of lymphedema. There is limited evidence for avoiding IV catheter placement and venipuncture in the affected arm following ALND and SLNB. Best practice is to assess the patient for risk factors of lymphedema before recommending selected evidence-based limb precautions.<br /><br /> The Oncology Care Model requires implementation of processes to reduce urgent care (UC), emergency department (ED), and hospital visits for patients on antineoplastic therapies, including oral antineoplastic agents.<br /><br /> The purpose of this project was to develop, implement, and initially evaluate an oral antineoplastic therapy program (OAP) and an oncology antineoplastic nurse navigator (OANN) role aimed at reducing UC, ED, and hospital visits.<br /><br /> This pilot project used a descriptive correlational design to analyze the impact of the novel role of the OANN on UC, ED, and hospital visits.<br /><br /> The OANN engaged 1,095 patients between January 1, 2019, and December 31, 2020. A reduction in UC, ED, and hospital visits was noted between 2019 and 2020 for patients followed by the OANN and enrolled in the OAP. Patients who were contacted by the OANN three or more times after starting their oral antineoplastic agent were less likely to be seen in UC or the ED or to be hospitalized. The novel role of the OANN within the overall OAP provided a significant benefit in reducing UC and ED visits and hospitalization for patients enrolled in the program.<br /><br />The OANN engaged 1,095 patients between January 1, 2019, and December 31, 2020. A reduction in UC, ED, and hospital visits was noted between 2019 and 2020 for patients followed by the OANN and enrolled in the OAP. Patients who were contacted by the OANN three or more times after starting their oral antineoplastic agent were less likely to be seen in UC or the ED or to be hospitalized. The novel role of the OANN within the overall OAP provided a significant benefit in reducing UC and ED visits and hospitalization for patients enrolled in the program.This article presents a case of a patient diagnosed with an indolent form of chronic lymphocytic leukemia (CLL). He was being followed with close observation when he was diagnosed with Richter transformation, an aggressive lymphoma that develops from CLL. The development of Richter transformation carries a poor prognosis, in part, because of underlying molecular changes that give rise to the transformation. The prognosis also relates to the difficulty in the patient's ability to receive chemotherapy because of poor marrow reserves from the disease or the residual impact of prior treatments. Advanced practice nurses who follow patients with CLL need to be aware of the potential for Richter transformation.Di(2-ethylhexyl) phthalate (DEHP) is a member of the phthalate ester chemical class that occurs commonly in the environment and to which humans are widely exposed. Lifetime exposure to DEHP is likely to occur, including during the in utero and early postnatal windows of development. To date, no carcinogenicity assessments of DEHP have used a lifetime exposure paradigm that includes the perinatal period (gestation and lactation). The National Toxicology Program (NTP) tested the hypothesis that exposure during the perinatal period would alter the DEHP carcinogenic response quantitatively (more neoplasms) or qualitatively (different neoplasm types). Two chronic carcinogenicity assessments of DEHP were conducted in which Sprague Dawley (HsdSprague Dawley SD) rats were exposed to dosed feed containing 0, 300, 1,000, 3,000, or 10,000 ppm DEHP for 2 years using different exposure paradigms. In Study 1, groups of 45 F0 time-mated females were provided dosed feed beginning on gestation day (GD) 6 through lactation. On postnatal day (PND) 21, groups of 50 F1 rats per sex continued on the study and were provided dosed feed containing the same DEHP concentration as their respective dam for 2 years. In Study 2, groups of 50 rats per sex, aged 6 to 7 weeks at study start, were provided dosed feed containing DEHP for 2 years. (Abstract Abridged).Di-n-butyl phthalate (DBP) is a phthalate used in the manufacture of consumer products such as plastics and personal care products. Widespread exposure in the population occurs throughout life, including during pregnancy and lactation. Because limited data are available in both animals and humans to evaluate DBP as a human carcinogen, the National Toxicology Program conducted 2-year studies of DBP in rats and mice. Time-mated female Sprague Dawley (HsdSprague Dawley SD) rats were exposed to 0, 300, 1,000, 3,000, or 10,000 ppm DBP in feed during gestation and lactation. Postweaning, F1 offspring consumed diets with the same exposure concentrations as the dam for 2 years (n = 50/sex/exposure group). Male and female adult B6C3F1/N mice were exposed to 0, 1,000, 3,000, or 10,000 ppm DBP in feed for 2 years (n = 50/sex/exposure group). Estimated average chronic chemical consumption was 16-17, 54-57, 152-169, and 510-600 mg DBP/kg body weight/day (mg/kg/day) in rats in the 300, 1,000, 3,000, and 10,000 ppm groups, respectively, and 105-112, 329-347, and 1,306-1,393 mg/kg/day in mice in the 1,000, 3,000, and 10,000 ppm groups, respectively. (Abstract Abridged).BACKGROUND This report describes a 63-year-old Polish man presenting with COVID-19 (Coronavirus Disease 2019) pneumonia in early 2020, before vaccines to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were available. Nine weeks following recovery from the initial infection, he tested positive again for SARS-CoV-2. CASE REPORT Man, age 63, was admitted to the Military Institute of Medicine on March 12, 2020, with body temperature 40°C, a cough, and breathlessness. On March 12, 2020, SARS-CoV-2 RNA was found in a nasopharynx smear. A chest X-ray (RTG) showed discrete areas of interstitial densities. On June 13, 2020, after 32 days of hospitalization and 2 negative real-time polymerase chain rection (RT-PCR) test results, patient was released home in good general condition. [https://www.selleckchem.com/products/sgc-cbp30.html buy SGC-CBP30] On July 23, 2020 he reported to the emergency room with fever of 39°C and general weakness. A nasopharynx smear confirmed SARS-CoV-2 infection. On admission, the patient was in moderately good condition with auscultatory changes typical for pneumonia on both sides of the chest.